HuM195 is a humanized, unconjugated, anti-CD33 monoclonal antibody. Fifty adult patients with relapsed or refractory AML were randomized to receive HuM195 at a dose of 12 or 36 mg/m 2 by intravenous infusion over 4 h on days 1-4 and 15-18. Patients with stable or responding disease received two additional cycles on days 29-32 and 43-46. HuM195 was given as first salvage therapy in 24 patients and as second or subsequent salvage therapy in 26 patients. Pretreatment blast percentage in the marrow was between 5 and 30% in 20 patients with the others having blast counts greater than 30%. The median age of patients was 62 years (range 26-86) and CD33 was detected in 95% of patients for whom immunophenotyping was available. Of 49 evaluable patients, two complete and one partial remission were observed. All three responses were in patients treated at the 12 mg/m 2 dose level and all had baseline blast percentages less than 30%. Decreases in blast counts ranging from 30 to 74% were seen in nine additional patients. Infusion-related events of fever and chills occurred in the majority of patients and were generally mild and primarily related to the first dose of antibody. No hepatic, renal or cardiac toxicities were observed and other adverse events such as nausea, vomiting, mucositis and diarrhea were uncommon or felt to be unrelated to HuM195. In addition, anti-HuM195 responses were not detected. HuM195 as a single agent has minimal, but observable, anti-leukemic activity in patients with relapsed or refractory AML and activity is confined to patients with low burden disease. No significant differences in clinical efficacy or toxicity were seen between the two dose levels of antibody. HuM195 was well tolerated with infusion-related fevers and chills the predominant toxicities seen. Meaningful clinical efficacy of this unconjugated monoclonal antibody may be realized only in patients with minimal residual disease, or in combination with chemotherapy.
Introduction
Current therapy for adults with acute myeloid leukemia has generally included cytosine arabinoside (Ara-C) in combination with an anthracycline antibiotic. 1 Results in adults have demonstrated significant heterogeneity in response to therapy. Previously untreated patients with de novo AML under age 60, and, in particular, those with favorable cytogenetic changes including t(8;21), inv (16) and t (15;17) are sensitive to current antileukemic chemotherapy. 2 In contrast, patients resistant to or relapsed from initial therapy, as well as those untreated patients with antecedent hematological disorders (AHD) and/or chromosomal abnormalities such as −5, −7, +8 or 11 q23 changes are clearly less responsive to chemotherapy. [2] [3] [4] HuM195 is a humanized murine monoclonal antibody directed against the cell surface myelomonocytic differentiation antigen, CD33, which is detectable in over 90% of patients with acute myeloid leukemia (AML). 5 The antibody consists of a human IgG1 framework that contains human constant regions and murine complementarity determining regions.
Initial development of this agent was conducted using the murine antibody, M195, a non-cytotoxic IgG2a mouse monoclonal antibody that binds to CD33. 6, 7 In vitro studies demonstrated that M195 was rapidly internalized after binding to the cell surface and mediated complement-dependent cytotoxicity against the human leukemia cell line, HL60. 8 Initial phase I clinical studies in patients with AML were conducted using the murine antibody M195. A preliminary dose-escalation study reported by Scheinberg et al 9 showed that trace-labeled 131 I-M195 rapidly and specifically targeted leukemic cells in vivo. There was dose-related delivery of isotope to the bone marrow and efficient internalization into target cells. Subsequently, a phase I trial showed that therapeutically labeled 131 I-M195 could eliminate large leukemic burdens in patients with relapsed and refractory disease. 10 Despite these antileukemic effects, repeated dosing of the murine antibody was limited by the development of human anti-murine antibody (HAMA) response.
The humanized antibody HuM195 was subsequently created which demonstrated rapid targeting of myeloid leukemic cells and was non-immunogenic. In addition, by virtue of its human IgG1 isotype framework, HuM195 could mediate antibody-dependent cellular cytotoxicity (ADCC) in vitro, which the murine antibody was not able to perform.
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Phase I studies with HuM195 were conducted in patients with relapsed or refractory AML. An initial study investigating the biodistribution, pharmacology and immunogenicity of HuM195 at doses of 0.5-10.0 mg/m 2 demonstrated complete bone marrow targeting without blood pooling of radiolabeled HuM195 following administration of 3 mg/m 2 of antibody. Partial saturation of CD33 binding sites on leukemic blasts, and re-expression of CD33 antigen at 72 h following administration occurred despite repeated dosing over a 3 week period. The 10 mg/m 2 dose level resulted in complete and prolonged saturation, and there was no evidence of a human antihuman antibody (HAHA) response at any dose. Of 13 patients enrolled, only one, treated at the highest dose level (10 mg/m 2 ), had a significant antileukemic response. 12 Given these data, as well as the observation that passive immunotherapy with high doses of murine M195 completely eliminated HL60 cells in an athymic mouse model, 13 a sub-sequent phase I evaluation was conducted using supersaturating doses of HuM195 in a similar advanced leukemia population. In a study involving 10 patients with relapsed or refractory myeloid leukemia, HuM195 was administered at a dose of 12, 24 or 36 mg/m 2 infused over 4 h daily on days 1-4 and 15-18. This study demonstrated that HuM195 at higher doses was well tolerated. Toxicities were primarily related to the infusion period, and included fever, rigors and transient hypotension. Pharmacokinetic data indicated that high serum levels and a prolonged half-life (Ͼ1 week) were achieved at all dose levels and that the CD33 antigen on leukemic cells remained saturated throughout the 4 week trial period. HAHA responses were not detected in any of the patients tested up to 4 months post treatment. Clinical responses were seen in four of 10 patients including one complete remission in a patient who received the lowest dose level (12 mg/m 2 ).
14 These initial studies demonstrated that higher doses and longer administration of HuM195 resulted in prolonged saturation of CD33 antigen binding sites, lack of immunogenicity, tolerable toxicity, and enhanced biological activity compared to lower doses. Although supersaturating doses (12 mg/m 2 and above) appeared better compared to lower doses, it was unclear whether doses above 12 mg/m 2 of HuM195 would result in greater efficacy. Therefore, a phase II study was conducted to evaluate the overall efficacy of HuM195 as a single agent in relapsed or refractory AML, as well as to compare in a randomized fashion, the relative safety and anti-leukemic activity of 12 mg/m 2 vs 36 mg/m 2 dose levels.
Materials and methods
Patients of at least 18 years of age with histologically documented relapsed or refractory AML (French-American-British (FAB) classification M3 excluded) were eligible for entry into the trial. Those individuals with a prior myelodysplastic syndrome, or having undergone a bone marrow transplant, were allowed. Patients were required to have a serum bilirubin and creatinine less than 2 mg/dl, a left ventricular ejection fraction that was normal according to institutional values, and a Karnofsky performance status of at least 50. The protocol was approved by the ethics committee of each participating institution, and written informed consent was obtained prior to the initiation of treatment. Eligible patients were randomized within 2 weeks of initial assessment to receive one of two dose levels (12 or 36 mg/m 2 ) of HuM195 supplied by Protein Design Labs (Fremont, CA, USA). HuM195 was administered as a 4 h intravenous infusion for 4 consecutive days on study days 1-4 and 15-18. Patients with stable or responding disease after two cycles of treatment received an additional two cycles of therapy on days 29-32 and 43-46.
At the investigator's discretion, stable or responding patients could receive continuation therapy of one 4 day cycle of HuM195 monthly for a maximum of six additional cycles or until documented disease progression.
All patients received acetaminophen 650 mg and diphenhydramine 25-50 mg with or without meperedol 25-50 mg prior to HuM195 to prevent or reduce infusion reactions. Supportive care including antibiotics and transfusions was given according to individual institutional guidelines.
Bone marrow aspirates and/or biopsies were obtained prior to initiation of therapy to assess the percentage of blasts in the marrow and determine morphologic classification according Leukemia to the FAB criteria. Although not a requirement for entry into the study, immunophenotypic evaluation for the myeloid cell surface marker CD33 was performed by flow cytometric method in all patients with adequate samples of blood or bone marrow aspirates.
Repeat marrow examinations were performed following cycles two and four of therapy and then monthly thereafter to assess remission status. Complete remission (CR) was defined as the achievement of a cellular marrow with Յ5% myeloblasts, a neutrophil count of Ն1.5 × 10 6 /l and a platelet count of Ͼ100 × 10 9 /l for a duration of 1 month or longer. In patients not meeting criteria for CR, evidence of antileukemic activity was assessed by evaluation of decreases in bone marrow blasts percentages from baseline levels.
Blood samples were obtained pretreatment and periodically after the start of treatment to assess the development of antibodies against HuM195. The presence of serum anti-HuM195 antibodies was determined using a sandwich enzyme linked imunosorbent assay (ELISA). HuM195 was used as the solidphase capture reagent; the binding of anti-HuM195 antibodies to the coated well was detected using horse radish peroxidaseconjugated HuM195. A murine anti-idiotypic antibody was used to calibrate the assay. Positive immunogenicity responses were reported in ng/ml of anti-idiotype (anti-id) equivalents with a limit of detection of 5 ng/ml of anti-id equivalents.
All discrete variables, including response rates, were compared between the groups by chi-squared analysis and where applicable by the Fischer's exact test; continuous variables were compared by the t-test or a nonparametric test as appropriate, after normalizing the distributions where needed. An 80% power (1-Z beta .) probability of avoiding false negatives was required to accept an absence of significant differences.
Patient characteristics
Overall, 50 patients, 25 per treatment arm, were entered into the trial. The clinical characteristics of the patients by dose level of HuM195 are shown in Table 1 . Thirty-one males and 19 females with a median age of 62 years (range 26-86) participated in the trial. The FAB classification included: M0 (9), M1 (13), M2 (10), M3 (0), M4 (11), M5 (1), M6 (1), M7 (3), unclassified (2) . The median Karnofsky performance status was 90 (range 50-100). All patients had received prior therapy for AML. Sixteen patients had never achieved a complete remission, whereas 34 had achieved at least one complete remission. Overall, HuM195 was given as first salvage therapy to 24 patients, as second salvage in nine patients, and as third or greater salvage therapy in 17 patients. No patients had undergone a prior marrow transplant. Pretreatment blast percentages in the marrow were greater than 30% in 28 patients, whereas 20 patients entered therapy with a blast count between 5 and 30%, and for one patient in each group, no pretreatment blast percentage was obtainable.
CD33 positivity was detected in 95% of the 41 patients for whom immunophenotyping data were available on either peripheral blood or bone marrow cells. A comparison of pretreatment characteristics, including age, number of prior chemotherapy regimens, time from initial diagnosis, baseline blast percentage, and CD33 positivity, did not demonstrate any statistical difference between the two treatment arms.
Antileukemic responses
Of the 50 study patients randomized, 49 were evaluable for response and toxicity. One patient who was randomized to the 36 mg/m 2 arm of the study, experienced rapid progression of AML and died prior to treatment with HuM195. Overall, two patients achieved a CR by full criteria and one more who enrolled with 44 000/l platelets would have achieved a CR except that the platelets never rose above 54 000/l ( Table 2 ). All three were treated at the 12 mg/m 2 dose level, and all three had baseline blast percentages of less than 30%. Both patients who achieved criteria for CR had baseline platelets and neutrophils above 100 000/l and 1500/l respectively, and although a decrease in blast counts to below 5% was observed, an improvement in hematologic parameters could not be demonstrated. One CR was durable, lasting more than 7 months, one was brief, with a duration of 2 months, and the CR lacking full criteria lasted 1 month. In addition, nine patients had documented decreases in bone marrow blast proportions ranging from 30 to 74% in response to therapy ( Table   Table 2 HuM195-induced responses 3). Of these nine patients with substantial bone marrow blast reductions, five were treated at the 12 mg/m 2 dose level, and all reductions were transient, with none lasting beyond 2 months, and none were associated with hematologic improvement.
Toxicity
Infusion-related toxicities, occurring on the day of HuM195 administration, were the most common adverse effects related to treatment. Common infusion-related side-effects were chills and fever (Table 4) , one or both occurring in over half of the patients, while 22% of patients experienced neither adverse event during or after infusion of HuM195. Chills occurred only on the first dose of cycle number 1 ('first-dose' phenomenon) in 87% of the 30 patients who suffered this adverse event. Overall, only two episodes of infusion-related chills were considered severe, one in each dose level group; each resolved promptly with medication (intravenous meperidine with or without diphenhydramine) and by interrupting the HuM195 infusion in one instance. Infusion-related fevers were generally more prolonged than chills, and also occurred less frequently as dosing cycles continued. None of these fevers were considered severe by the investigators. Hypotension and the other commonly observed infusion-related side effects (Table 4) were only mild to moderate in severity, resolved promptly and usually required no specific treatment. Of note, mild, self-limited facial flushing was observed in conjunction with HuM195 infusion in four patients, all in the 36 mg/m 2 dosing group and all as a first-dose phenomenon. HuM195 therapy was discontinued in only one patient and the rate of infusion was interrupted or reduced in 13 instances (12 patients) representing less than 4% of the 360 doses received by the 49 patients treated in the study.
Apart from the infusion-related events, other non-hematologic toxicities were uncommon. Treatment-related cardiotoxicity was not observed, nor was there HuM195-related hepatic toxicity as manifested by hyperbilirubinemia or other liver function test elevations. Nausea and vomiting related to HuM195 infusion occurred in less than 15% of patients (Table  4 ) and other adverse events such as mucositis and diarrhea were uncommon during the study period and were felt to be unrelated to HuM195.
Of the 49 HuM195-treated patients, 20% died during the planned 8-week treatment period. The causes of these 10 deaths (five in each dose level group) were progression of AML (three), sepsis (three), and cerebral and/or pulmonary hemorrhage (four). The causes of death after the 8 week treatment period were progression of leukemia (55%), infections and sepsis (42%) and intracerebral hemorrhage (3%). Antibodies to HuM195 were not detected.
Discussion
Resistance to chemotherapy mediated by several variables, including overexpression of multi-drug resistance (MDR) or anti-apoptotic genes, continues to be a significant factor leading to low cure rates for the majority of adults with AML. 15, 16 Therapeutic strategies such as monoclonal antibodies, that can potentially induce cell death via pathways alternative to those of cytotoxic chemotherapy, may lead to responses in chemotherapy-resistant AML and, ultimately, may result in better outcomes when combined with chemotherapy in less resistant patients. HuM195, a humanized monoclonal antibody directed against CD33 has been shown to induce cell death by activation of complement as well as by antibody-directed cellular cytotoxicity, which is enhanced in the presence of interleukin-2 in vitro. 17 Phase I studies demonstrated that HuM195 doses 12 mg/m 2 and above resulted in complete saturation of CD33 binding sites and no development of HAMA or HAHA. It was unclear whether doses above 12 mg/m 2 had greater efficacy and therefore the phase II evaluation was conducted comparing two dose levels.
The results of this randomized phase II study indicate that HuM195 is well tolerated and has modest, but nevertheless, observable anti-leukemic activity in patients previously shown to be refractory to chemotherapy. The present study confirms, in a larger cohort of AML patients, the safety and tolerability of HuM195 that was observed in the phase I studies. As with other monoclonal antibody therapies, infusion-related events were the primary toxicities associated with administration of HuM195, and were similar to the experiences reported with other monoclonal antibodies such as rituximab in follicular lymphoma or trastuzumab in breast cancer patients. 18, 19 The incidence and severity of treatment-related toxicities, primarily fever and chills during and/or immediately following the infusion of HuM195, were equivalent for patients treated at dose levels of either 12 or 36 mg/m 2 , indicating that HuM195 can be administered safely at higher doses. Other organ-speLeukemia cific toxicities, including gastro-intestinal, mucosal, hepatic, renal and cardiac were mild or non-existent, suggesting the potential for combination with other agents.
As a single agent HuM195 had only minimal efficacy in patients with relapsed or refractory AML. Since only a few complete remissions were observed, it is difficult to judge the relative efficacy of the two dose levels of HuM195. However, since all the responses were observed at the 12 mg/m 2 dose, no apparent advantage of three-fold higher doses of HuM195 could be documented in the population of AML patients treated in this study. However, the higher dose of HuM195 was comparable to only 1 mg/kg of antibody, far lower than the 10+ mg/kg doses of other anti-cancer antibodies. 18, 19 In patients with high leukemic blood and marrow burdens only transient decreases in blast counts were observed and none of the patients with blast counts Ͼ30% in the marrow achieved a CR or PR. Complete or partial responses were confined to patients with low-burden disease, with a 15% response rate seen in this group.
The response rate seen in this study, although proof of antileukemic activity, is still quite modest, suggesting that agents like HuM195, which rely on complement or cell-mediated cytotoxicity, may have efficacy as single agents only in patients with minimal levels of leukemia. This efficacy in minimal residual leukemia has been documented in a study by Jurcic et al 20 in patients with acute promyelocytic leukemia (APL) in CR with minimal disease documented by RT-PCR for PML/RARalpha positivity. In this experience, 11 of 22 patients converted to a RT-PCR negative state following treatment with HuM195 at 3 mg/m 2 for six doses. 20 Whether the greater efficacy of HuM195, at relatively low doses, was due to the lower burden of leukemia in these patients, or possible greater sensitivity of APL to anti-CD33 antibody therapy, cannot be determined from the current data available.
Recent data have demonstrated that CD33 may function as an inhibitory receptor within myeloid cells and that engagement of CD33 by anti-CD33 antibodies in vitro results in a dose-dependent induction of cell death via apoptosis. Maximum inhibitory effects were seen at relatively high concentrations (10 g/ml) of antibody. 21, 22 This finding suggests that concentrations of anti-CD33 monoclonal antibodies higher than those achieved in this study might result in greater anti-leukemic efficacy by activating an apoptotic pathway.
Alternative strategies in the development of monoclonal antibody therapy in AML have included the use of antibodies as a means of delivering cytotoxic agents or radioisotopes directly to the leukemic blast. Gemtuzumab ozogamicin, a humanized IgG1 anti-CD33 monoclonal antibody conjugated to calicheamicin, a potent DNA-damaging anti-tumor antibiotic, has demonstrated significant activity in relapsed AML, with less extramedullary toxicity when compared historically to systemic chemotherapy. 23 Despite this advantage, the antibody itself has minimal ability to mediate complement or ADCC and calicheamicin may be affected by multi-drug resistance mechanisms in AML similar to anthracyclines.
In summary, HuM195 at supersaturating doses is well tolerated, but as a single agent has only minimal activity in patients with AML in full relapse. Further development of this agent in AML patients will more likely occur as post-remission therapy in patients in clinical CR, or in combination with chemotherapy in patients with active AML.
